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The effect of Naturo Fruit Bars in altering metabolic parameters in type-2 diabetes was tested in a 
randomized open-label clinical trial on healthy volunteers and type-2 diabetics. To determine the 
safety of the fruit bars, 13 healthy volunteers and 10 type-2 diabetics were administered with 2, 3, 4  
fruit bars on day 0, 7 and 14 and blood glucose levels were determined at time ‘zero’ and two hours 
after consumption.  In the efficacy study 18 type-2 diabetics consumed two bars of apple flavor 
without added sugar per day for 12 weeks. Blood glucose, insulin, hemoglobin A1C, lipid profile and 
adiposity were determined on day zero and at the end of study.  Results of the safety study indicated 
that consumption of 2, 3 or 4 fruit bars did not elevate blood glucose levels in both healthy and type-
2 diabetes subjects. Consumption of two bars per day for 12 weeks in type-2 diabetics did not 
increase the blood glucose levels. The levels of cholesterol, HDL cholesterol, LDL cholesterol, 
triglycerides and Body Mass Index did not alter. Consumption of Naturo fruit bars did not increase 
the blood glucose levels and thus can be used as a substitute for healthy food in type-2 diabetics 
without any undesirable effects.  
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INTRODUCTION  
Diabetes mellitus is a metabolic disorder 
and its prevalence is an important global health 
problem (King et al., 1998). In 1985 an 
estimated 30 million people world-wide had 
diabetes, and in 2010, there were 285 million 
cases. This number is projected to increase to 
about 439 million by 2030 (Shaw et al., 2010). 
The prevalence of diabetes is higher in 
developed countries than in developing 
countries, but the incidence of diabetes in 
developing countries is likely to increase at a 
higher rate (Mohan V et al., 2010). Increased 
urbanization, economic development and job 
related sedentary habits in developing countries 
are likely the contributory factors for the 
expected rise in the cases of diabetes (Wasir JS 
and Misra A, 2004).  
In recent years, several nutritional 
supplements specifically designed for diabetic 
patients have been commercialized, which are 
unlikely to increase the post-prandial blood 
glucose levels compared to glucose or high 
glycemic foods (Fix et al., 2000). Liquid 
nutritional supplements (e.g. Glucerna) have 
been shown to reduce the post-prandial blood 
glucose levels in diabetes patients (Gonza´lez-
Ortiz M et al., 2000).  Many snacks/bars are 
available as nutritional supplements for diabetic 
subjects, but their effect on blood glucose 
levels, insulin secretion and glycated 
hemoglobin (HbA1C) and lipid profile in 
diabetes has not been examined systematically.  
The aim of the present study was to investigate 
the effect of chronic administration of Naturo 
fruit bars (manufactured by Naturo Food and 
Fruit products Private Ltd, Bangalore, India) on 
metabolic parameters in patients with type-2 
Diabetes mellitus.  Earlier we determined the 
Glycemic Index (GI) value of Naturo fruit bar 
(apple flavor) and found it to be 38.50 [Reddy 
KK et al., 2009].  There are very limited 
supplements available in India to cater to the 
needs of the increasing number of diabetes 
population, who are concerned and selective in 
taking appropriate snacks. It is anticipated that 
NFB are likely to serve as a healthy food 
choice for diabetic population in India.  
MATERIALS AND METHODS  
Investigational Product 
Naturo fruit bars (Photo slide 1) were 
prepared from fresh fruits by a unique process 
without any artificial additives and available in 
different flavors (Apple, Mango, Pineapple and 
Guava) containing with or without added 
sugars. The present study is focused on the 
Naturo Fruit bar, apple flavor without added 
sugars.  Nutritional information of the Naturo 
fruit bar (apple flavor): Serving size: one fruit 
bar (20 g): calories (65.48 KCal), protein 
(0.35 g), carbohydrate (15.73 g), sugar 
(13.48 g), total fat (0.15 g), saturated fat 
(0.0004 g), dietary fiber (1.55 g), sodium 
(10 mg), potassium (120.92 mg), calcium 
(0.21 mg), Iron (0.91 mg), vitamin C (2.4 mg) 
and vitamin A (43.51 IU).  In view of low 
carbohydrate, fat and sugar content, but 
enriched with fiber and protein, the NFB can be 
considered as a substitute for healthy food in 
type-2 diabetic patients.  
Study design  
A randomized open-label, clinical trial was 
carried out on normal healthy volunteers and 
type-2 diabetic patients at Sugen Life Sciences 
Pvt Ltd, Tirupati, India. The protocol for the 
study was adhered to Good Clinical Practice 
(GCP) guidelines and followed the 
recommendations of the World Medical 
Association Declaration of Helsinki. The study 
protocol was approved by an Independent 
Ethics Committee (IEC) of of Snehal Hospitals, 
Bombay, India.   Informed Consent Form (ICF) 
was obtained from all healthy volunteers and 
diabetes patients and all subjects were closely 
monitored and recorded for any adverse events 
throughout the study.  
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Photo Slide 1: Displaying the market available Naturo Fruit Bars
Subject selection parameters  
The clinical trial was initiated to assess the 
safety in healthy volunteers and diabetic 
patients followed by efficacy study in diabetic 
subjects only. In safety study, dose escalation 
and the safety of the NFB was determined in 13 
adult healthy volunteers and 10 adult type
diabetes subjects.  In efficacy study, NFB was 
administered for 12 weeks in 18 type 2 
diabetics to monitor the levels of blood 
glucose, insulin, HbA1C and lipid profile. 
There were no drop-outs in the present study.
The age range of the subjects in the present 
study is 30–70 years.  Both healthy volunteers 
and type-2 diabetes subjects were non
(BMI < 25 kg/m
2
), non-smoking and non
alcoholic. All the healthy volunteers were in 
good health, as determined by medical history 
and physical examination; no history of 
hypertension, hepatic and renal disease, 
coronary artery disease, and or type
Diabetes mellitus was reported.  The inclusion 
criteria for diabetic subjects were those taking 
standard medication of Oral Hypoglycemic 
Agents (OHA) advised by the physician for the 
past three months, whose fasting blood glucose 
levels are maintained in the range of 100
120 mg/dL and otherwise normal in other 
clinical and laboratory parameters. The 
exclusion criteria: Diabetic patients curr
under treatment for heart disease, cancer, post
surgery patients, tuberculosis and other chronic 
diseases, subjects who are bedridden for 
chronic diseases for prolonged time and kidney 
diseases, users of drugs which exert 











intoxication and pregnant wo
of diabetes in the study subjects was between 
3–7 years.  During the study period the subjects 
were given clear instructions by the physician 
not to deviate from their regular drug intake, 
diet regime and physical exercise. Throughout 
the study, principal investigator and clinical 
research coordinator have monitored the 
subjects at regular intervals for any events.  
Weight and height were recorded with the 
subjects wearing light clothing without shoes. 
Height was measured and rounded off 
nearest centimeter, with the subjects standing in 
erect posture. Body Mass Index (BMI) was 
calculated as weight in kg divided by the height 
in meter square. Waist girth was measured at 
the level of umbilicus with person breathing 
silently and hip measured as standing inter
trochanteric girth according to the method 
specified by Weiner and Lourie (Weiner JS and 
Lourie JA et al., 1981). Waist Hip Ratio 
(WHR) was calculated from the circumferences 
of waist and hip. Systolic and diastolic 
pressures were considered in Korotkoff phase I 
and V respectively as specified by Rose 
(Rose GA et al., 1982).  Diabetic subjects were 
requested to withdraw drug intake prior to 
blood sample collection.  Fasting (11h) venous 
blood collected from the patients was 
to clot for 30 min at room temperature and then 
centrifuged. The resulting plasma 
separated into two aliquots. The first aliquot 
was used for the measurement of glucose, total 
cholesterol, high-density lipoproteins (HDL), 
triglycerides and HbA1
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according to the Frieldwald et al., (1982) 
formula (total cholesterol- HDLC/5 + TG).  
The second aliquot was frozen at −20
0
 C and 
processed within 30 days for the estimation of 
insulin by radioimmunoassay method with an 
intra- and inter-assay coefficient of variation of 
< 4.4 and 6.9 % respectively.  Blood glucose 
was determined by the glucose-oxidase method 
with an intra- and inter-assay coefficient of 
variation of < 1 %. Serum lipid levels (total 
cholesterol, HDL cholesterol and triglycerides) 
and HbA1C were measured by enzymatic 
methods with an intra- and inter-assay 
coefficient of variation of < 3 %. The HDL 
cholesterol was estimated after selective 
precipitation of non-HDL fractions.  
 
In the safety study, all the subjects 
consumed an iso-caloric diet (69 Kcal, 15 g of 
carbohydrate, 1.2 g of protein, 0.2 g of total fat) 
through the personal substitution by the 
investigators on scheduled visit to the clinic 
(day 0, 7 and day 14). After the withdrawal of 
first blood sample, an iso-calorie diet was 
provided to all the subjects apart from Naturo 
fruit bars. Subjects were provided with 2, 3, 4 
Naturo fruit bars on day 0, 7, 14 respectively 
(one time supplementation) and allowed to 
consume the bars in the clinic itself after taking 
the breakfast, under the supervision of the 
physician. To ascertain the safety of the NFB 
we conducted dose escalation study of fruit 
bars initially in the healthy volunteers followed 
by the type-II diabetes subjects.  After the 
intake of fruit bars the subjects stayed in the 
clinic and were under the supervision of the 
physician and the blood was withdrawn after 
two hours of consumption of NFB.  In addition 
these volunteers did not report any adverse 
effects after completion of the short-term study. 
Blood samples were drawn (fasting) and after 
two hours upon consumption of Naturo fruit 
bars for the estimation of glucose levels.  In the 
efficacy study, 18 adult type-2 diabetes patients 
were recruited and instructed to consume two 
NFB / day for 12 weeks. The protocol adopted 
for efficacy study is same as in safety study.  In 
the diabetes patients (safety study), post-
prandial blood sugar levels (Table-2) were 
reduced after the consumption of two Naturo 
fruit bars. But the consumption of three and 
four bars moderately elevated the post-prandial 
blood sugar. This allowed us to select two fruit 
bars for efficacy study.  Fasting and post-
prandial blood glucose levels were monitored 
weekly. On day ‘zero’ and on 12th week, 
fasting and post-prandial blood glucose, lipid 
profile (Cholesterol, HDL-Cholesterol, and 
Triglycerides), HbA1C and insulin levels were 
determined.  Blood pressure, pulse rate, overall 
and abdominal obesity were recorded.  
Analysis  
Statistical analysis was performed using the 
statistical package (SPSS) version 16.0. Sample 
size was calculated using a clinical trial 
formula as described (Jayeseelan L and Rao 
PSS, 1989). Utilizing a standard deviation of 
0.7, a sample size of 18 subjects was chosen to 
detect the effect with 80% power and a two-
sided significance level of 5 % was adopted. 
Initially the data was subjected to normality 
distribution.  In descriptive statistics, results 
were expressed as mean ± SD unless otherwise 
specified. One-way analysis of variance 
(ANOVA) and student’s‘t’ test was applied 
where necessary.  
RESULTS  
The demographic and metabolic variables 
for the safety study are shown in table-1 for 
healthy volunteers and diabetes patients. As 
shown in table-1 no significant difference was 
observed in the overall obesity between healthy 
volunteers compared to type-2 diabetic 
patients, however, a significant difference was 
observed in abdominal obesity (p < 0.05). 
Mean systolic blood pressure was higher in 
diabetes patients (118.45 ± 6.82 vs 
113.11 ± 10.28). Mean total cholesterol 
(163.70 ± 27.93 vs 181.03 ± 23.49) and LDL 
cholesterol (101.45 ± 28.67 vs 117.23 ± 20.92) 
were lower in diabetic patients when compared 
to healthy volunteers with no change in 
triglycerides and HDL cholesterol and there 
were no adverse events throughout the study. 
These results indicate that all the subjects, both 
healthy volunteers and diabetes patients, have 
similar overall metabolic profiles.  
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Table.1 Demographic and metabolic profile of the study subjects (data as Mean ± SD) 




Age (years) 37.28 ± 7.16 45.80 ± 5.27 
Body Mass Index (Kg) 20.85 ± 2.30 20.92 ± 2.60 
Waist Hip Ratio (WHR) 0.848 ± 0.06   0.890 ± 0.04* 
Systolic blood pressure 113.11 ± 10.28           118.45 ± 6.82 
Diastolic blood pressure 78.03 ± 5.67 78.95 ± 5.23 
Pulse rate 69.97 ± 4.91 70.80 ± 4.66 
Total cholesterol 181.03 ± 23.49 163.70 ± 27.93 
HDL cholesterol 41.58 ± 5.68 42.50 ± 4.77 
LDL cholesterol 117.23 ± 20.92 101.45 ± 28.67 
Triglycerides 119.76 ± 38.93 126.95 ± 44.26 
*p<0.05 
Changes in the post-prandial blood glucose 
levels upon the consumption of NFB in both 
healthy and diabetic subjects were shown in 
table-2. These results show that consumption of 
two NFB decreased the post-prandial blood 
glucose (P < 0.0001) in diabetic subjects.  
Further, administration of 3 and 4 NFB bars 
moderately elevated the post-prandial glucose; 
however this elevation did not increase the 
base-line post-prandial glucose levels in 
diabetic subjects.  In healthy volunteers the 
consumption of two NFB decreased the blood 
glucose.  Subsequent administration of 3 and 4 
fruit bars showed an elevation from the base 
line glucose levels with some fluctuations in 
healthy volunteers.  Overall, the F-values 
indicate that the fluctuation in post-prandial 
blood glucose levels from the base line values 
is significant in both healthy and diabetic 
subjects. Because two fruit bars were preferred 
by a majority of the subjects, this dose was 
chosen for the efficacy study (12-week) in 
type-2 diabetes patients.  
 
Table.2 Mean values of fasting and post-prandial blood glucose levels in healthy and diabetic 




Type II Diabetes 
(N=10) 
Fasting 74.0 ± 10.6 117.2 ± 8.5 
Postprandial (2hrs) after test glucose:   96.3 ± 14.2*   145.1 ± 9.1* 
2 NFBs   91.9 ± 13.0* 126.1 ± 9.0 
3 NFBs   95.3 ± 11.3* 129.0 ± 7.4 
4 NFBs   99.0 ± 14.3*   131.6 ± 6.4* 
*F value for post-prandial blood glucose in healthy subjects=7.60; P < 0.05 
*F value for post-prandial blood glucose in diabetic subjects=15.44; p < 0.05 
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Mean differences for overall and abdominal 
obesity as well as on blood pressure did not 
show significant variation between day ‘zero’ 
and at the end of the 12-
Significant (p < 0.05) reduction in fasting blood 
glucose levels from day ‘zero’ to 12 weeks was 
observed in type-2 diabetes patients. There was 
a decrease in HbA1C (p < 0.11) and an increase 
in insulin levels between day ‘zero’ and 
towards the end of the study (p
extremities in mean difference (95
altered S.E failed to show significant difference 
for HbA1C and insulin between day ‘zero’ and 
at the end of the study.  Similarly, there was no 
significant changes in lipid profile (Cholesterol, 
HDL-cholesterol, LDL-cholesterol and 
Figure 1: Alterations in blood glucose levels in type
 
 
Changes in the levels of fasting and post
with two Naturo fruit bars for a period of 12 weeks.  Each point in the graph represents mean values observed on 
every week. One-way analysis of variance was applied to find out the chan
value = 2.252: P < 0.01) and post-prandial blood gluco
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week study.  
 < 0.08). The 
 % CI) with 
triglycerides) in the subjects following the 
consumption of two fruit bars for 12 weeks. 
Alterations in blood glucose levels in type
2 diabetes subjects upon consumption of two 
NFB for twelve weeks are
gradual decrease in both fasting and post
prandial blood glucose levels was observed in 
diabetic patients upon consumption of NFB. 
Overall these results indicate that the window 
between the fasting and post
levels decreased from day ‘zero’ to 12th week
(p < 0.05). In order to attain the linear growth 
rate for both fasting blood sugar (FBS) and 
post-prandial (PPBS) a regression line is fitted 
and observed that the rate of decrease for FBS 
is – 0.7 and for PPBS it is 
-2 diabetes patients administered with 
Naturo Fruit Bars for twelve weeks 
-prandial blood glucose levels in type-2 diabetes patients administered 
ges in fasting blood glucose (F
se (F-value = 4.109: P < 0.001).  The regression equation is 
Linear Growth Rate {( /)*100} for FBS = − 0.7 and for PP
y = -1.0157x + 116.14
y = -2.9328x + 168.78
3 4 5 6 7 8 9 10 11 12
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DISCUSSION  
Since prevalence of type-2 diabetes mellitus 
is increasing, offering nutritional supplements 
that improve glycemic control without any 
adverse effects is critical in the long- term 
management of diabetes patients.  In the 
present study, the safety of NFB consumption 
in type-2 diabetes patients was evaluated in a 
well-controlled clinical trial.  No adverse 
events were recorded throughout the study. 
The results presented in the safety study 
demonstrate that, consumption of 
two/three/four NFB did not increase the post-
prandial blood glucose levels in healthy 
volunteers and diabetes subjects. Based on the 
results of the safety study, an efficacy study 
over a period of 12 weeks (two fruit bars/day) 
was performed. The objective of this study was 
to determine whether consumption of NFB for 
longer periods of time has any effect on blood 
glucose levels and metabolic profile in type-2 
diabetes patients. In addition, this study 
allowed us to monitor for any adverse effects 
and changes in key biochemical parameters.  
The results of the long-term study 
demonstrate that consumption of two NFB 
everyday over a period of 12 weeks did not 
increase the blood glucose levels and has no 
adverse effects in type-2 Diabetes mellitus 
patients. Interestingly, NFB produced a 
significant decrease in both fasting and post-
prandial blood glucose levels after 12 weeks of 
consumption compared to day ‘zero’ (Fig.1). 
These results are in agreement with earlier 
studies by Gonza´lez-Ortiz et al., 2006, that 
nutritional supplements containing 
carbohydrates of low glycemic value has 
decreased the post-prandial blood glucose. In 
our earlier studies the GI value of NFB (apple 
flavor) was found to be 38.50 (Reddy KK et 
al., 2009).  Peters et al., 1992 showed that 
Glucerna (70 g carbohydrates/L) in type-1 
diabetes patients produced a decrease in basal 
glucose in comparison with Enrich and Ensure 
HN supplements, which contain 146 and 141 g 
of carbohydrates/L respectively. Similarly, Tsai 
et al., 1987 in their study shown that the 
supplementation of 10 g of soy polysaccharides 
(low GI value) showed a diminished post-
prandial glucose with no change in insulin in 
type-2 diabetes patients. The carbohydrate 
content of the Naturo fruit bar (15.73 g) was 
relatively lower when compared to HN 
supplements, which could be a key determinant 
in altering post-prandial glucose levels.  
A study (Jayagopal et al., 2002) showed 
that nutritional supplementation of soy protein 
(containing 132 mg/day isoflavones) reduced 
post-prandial glucose in post-menopausal 
women with type-2 diabetes. Similar to this 
study we also observed decreased post-prandial 
blood glucose in diabetic patients consuming 
Naturo fruit bars for 12 weeks. However, we 
observed no significant decrease in HbA1C 
levels. Future studies with large population size 
may explain the significance of this 
observation.  
Previous studies of Gonza´lez-Ortiz et al, 
(2006) using Glucerna-SR showed that 
administration of 75 g of glucose decreased the 
blood glucose and insulin concentration in 
addition to the total insulin secretion with an 
increment in the insulin sensitivity in healthy 
volunteers. The results from  our study are in 
agreement with the above studies, in that a 12-
week supplementation of a Naturo fruit bar 
(containing 15.73 g of carbohydrate, 65.48 
calories and 1.55 g of dietary fiber) reduced the 
fasting and post-prandial blood glucose levels 
(p < 0.05). Nutritional supplementation with 
28 % dietary fiber has been shown to reduce 
total cholesterol and LDL levels (Brown L et 
al., 1999). In the present study, 
supplementation of NFB did not affect blood 
lipids (Cholesterol, HDL cholesterol, LDL 
cholesterol and Triglycerides) and obesity in 
type-2 diabetes patients. It is possible that 
intake of NFB for longer-term (more than 12 
weeks) may have some influence on insulin and 
HbA1C.  
CONCLUSION 
In conclusion, the study demonstrates that 
consumption of NFB (Apple flavor without 
added sugar) does not increase blood glucose 
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levels and may have beneficial effects and may 
be used as a substitute for healthy food in type-
2 diabetes patients without any side-effects. We 
hope that studies like this on indigenously 
developed products would offer high benefit to 
the increasing number of diabetes patients (~40 
million) in India.  
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